MedTrace Logo

Glycemic Variability of Combination Therapies in T2DM

NCT07442006 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2026-03-02

No results posted yet for this study

Summary

Glycemic Variability of Combination Therapies in T2DM

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Empagliflozin/Metformin

5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)

DRUG

Anagliptin

100 mg, for 12 weeks (PO, BID)

DRUG

Metformin

500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)

DRUG

Empagliflozin/Linagliptin

10/5 mg, for 12 weeks (PO, QD)

Sponsors & Collaborators

Principal Investigators

  • Sung Rae Kim · The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-29
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07442006 on ClinicalTrials.gov